01:46 PM EDT, 08/13/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares rose nearly 3% in recent trading Tuesday after the company reported its Q2 results.

Candel booked a diluted net loss of $0.74 per share, widening from a loss of $0.33 a year earlier.

No comparable estimates were available on Capital IQ.

As expected, no revenue for the quarter ended June 30 was reported.

The company said it had $21.5 million in cash and cash equivalents, and expected it to fund operations through Q1 2025.

Price: 5.74, Change: +0.16, Percent Change: +2.87